Antihypertensive efficacy of indapamide SR in hypertensive patients uncontrolled with a background therapy: The NATIVE study

Current Medical Research and Opinion

Volumn 23, Issue 12, 2007, Pages 2929-2936

  Akram, J ^a   Sheikh, U E ^a   Mahmood, M ^a   Donnelly, Richard ^b,c  

^a KING EDWARD MEDICAL UNIVERSITY   (Pakistan)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Antihypertensive drugs; Indapamide sustained release; South Asian population; Uncontrolled hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INDAPAMIDE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; OUTCOME ASSESSMENT; PAKISTAN; PHYSICIAN; STATISTICAL SIGNIFICANCE; SUSTAINED RELEASE FORMULATION; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; INDAPAMIDE; MALE; MIDDLE AGED; OBSERVATION; PAKISTAN;

EID: 37749031862     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X242674     Document Type: Article

References (28)

1. Ezzati M, Lopez AD, Rodgers A, et al.; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60
2. Chobanian AV, Bakris GL, Black HR, et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood pressure: the JNC 7 report. JAMA 2003;289:2560-72
3. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
4. Williams B, Poulter NR, Brown MJ, et al.; British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85
5. Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-13
6. Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens 2005;18(2 Pt 1):287-94
7. Prevost G, Phan TM, Mounier-Vehier C, Fontaine P. Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen). Diabetes Metab 2005;31:479-85
8. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17
9. Roux O, Chapellier M, Czernichow S, et al. Determinants of hypertension control in a large French population of treated hypertensive subjects. Blood Press 2006;15:6-13
10. Gu Q, Paulose-Ram R, Dillon C, Burt V. Antihypertensive medication use among US adults with hypertension. Circulation 2006;113:213-21
11. Alonso Moreno FJ, Divison Garrote JA, Llisterri Caro JL, et al. Primary care physicians behaviour in inadequate blood pressure control. Aten Primaria 2005;36:204-10
12. Lacourciere Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005;27:1013-21
13. Ruilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005;27:578-87
14. Brown MJ, Cruickshank JK, Dominiczak AF, et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003;17:81-6
15. Sassard J, Bataillard A, McIntyre H. An overview of the pharmacology and clinical efficacy of indapamide sustained release. Fund Clin Pharmacol 2005:19:637-45
16. Leonetti G. Clinical positioning of indapamide sustained release 1.5 mg in management protocols for hypertension. Drugs 2000;59(Suppl. 2):27-40
17. Mimran A, Weir MR. Angiotensin-receptor blockers and diuretics - advantages of combination. Blood Press 2005;14:6-11
18. Ambrosioni E, Safar M, Degaute JP, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group. J Hypertens 1998;16:1677-84
19. Emeriau JP, Knauf H, Pujadas JO, et al.; European Study Investigators. A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens 2001;19:343-50
20. Leonetti G, Emeriau JP, Knauf H, et al.; European Study Investigators. Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. Curr Med Res Opin 2005;21:37-46
21. London G, Schmieder R, Calvo C, Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT study Am J Hypertens 2006:19:113-21
22. Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000;18:1465-75
23. Marre M, Garcia-Puig J, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR study (Natrilix SR versus Enalaril Study in hypertensive Type 2 diabetics with MicrOalbuminuRia) J Hypertens 2004;22:1613-22
24. Moser M. New-onset diabetes in the hypertension treatment trials: a point of view. Clin Hypertens (Greenwich) 2004;6:610-13
25. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies. Drug Saf 2001;24:1155-65
26. Malacco E, Vari N, Capuano V, et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003;25:2765-80
27. Wang JG, Staessen JA. Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials. J Clin Hypertens 2003;5:66-75
28. Lip GYH, Barnett AH, Bradbury A. Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. J Hum Hypertens 2007;21:183-211